Veracyte (VCYT) Competitors $31.90 +0.38 (+1.19%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. ADPT, BEAM, GH, TWST, TXG, RDNT, SHC, OPCH, BTSG, and NAKAShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Adaptive Biotechnologies (ADPT), Beam Therapeutics (BEAM), Guardant Health (GH), Twist Bioscience (TWST), 10x Genomics (TXG), RadNet (RDNT), Sotera Health (SHC), Option Care Health (OPCH), BrightSpring Health Services (BTSG), and KindlyMD (NAKA). These companies are all part of the "medical" sector. Veracyte vs. Its Competitors Adaptive Biotechnologies Beam Therapeutics Guardant Health Twist Bioscience 10x Genomics RadNet Sotera Health Option Care Health BrightSpring Health Services KindlyMD Adaptive Biotechnologies (NASDAQ:ADPT) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations. Do institutionals & insiders believe in ADPT or VCYT? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 1.4% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, ADPT or VCYT? Adaptive Biotechnologies has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Is ADPT or VCYT more profitable? Veracyte has a net margin of 5.50% compared to Adaptive Biotechnologies' net margin of -59.07%. Veracyte's return on equity of 6.07% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-59.07% -60.93% -23.03% Veracyte 5.50%6.07%5.53% Which has better earnings and valuation, ADPT or VCYT? Veracyte has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M11.07-$159.49M-$0.82-15.87Veracyte$445.76M5.75$24.14M$0.3398.73 Do analysts rate ADPT or VCYT? Adaptive Biotechnologies currently has a consensus target price of $12.38, suggesting a potential downside of 4.90%. Veracyte has a consensus target price of $40.90, suggesting a potential upside of 25.53%. Given Veracyte's higher probable upside, analysts plainly believe Veracyte is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Does the media favor ADPT or VCYT? In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Veracyte. MarketBeat recorded 10 mentions for Adaptive Biotechnologies and 9 mentions for Veracyte. Veracyte's average media sentiment score of 1.37 beat Adaptive Biotechnologies' score of 1.36 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVeracyte beats Adaptive Biotechnologies on 11 of the 16 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.56B$6.90B$5.76B$9.85BDividend YieldN/A1.22%6.67%4.51%P/E Ratio98.6226.0675.7726.43Price / Sales5.7570.07547.72119.09Price / Cash29.5321.6037.0558.92Price / Book2.154.9011.346.06Net Income$24.14M$178.27M$3.29B$266.28M7 Day Performance7.39%-0.86%0.18%-0.33%1 Month Performance30.27%2.52%6.30%3.43%1 Year Performance9.44%10.03%57.50%23.10% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte3.2016 of 5 stars$31.90+1.2%$40.90+28.2%+6.7%$2.51B$445.76M96.73790Positive NewsADPTAdaptive Biotechnologies3.3353 of 5 stars$12.67-2.5%$12.38-2.3%+199.3%$1.98B$178.96M-15.45790Positive NewsBEAMBeam Therapeutics2.5358 of 5 stars$16.44-1.2%$48.45+194.7%-23.0%$1.68B$60.27M-3.65510News CoveragePositive NewsGHGuardant Health4.3114 of 5 stars$61.88+0.8%$57.50-7.1%+152.0%$7.66B$739.02M-18.472,021News CoveragePositive NewsAnalyst ForecastGap DownTWSTTwist Bioscience3.9095 of 5 stars$27.39-4.2%$49.40+80.4%-35.2%$1.73B$312.97M-18.89990Positive NewsTXG10x Genomics4.1523 of 5 stars$14.07-1.6%$13.54-3.8%-40.7%$1.78B$610.78M-20.101,240Positive NewsRDNTRadNet4.0588 of 5 stars$69.59-0.7%$71.60+2.9%+15.3%$5.39B$1.83B-347.9311,021Positive NewsAnalyst ForecastSHCSotera Health2.3042 of 5 stars$16.39-0.2%$16.00-2.4%+0.6%$4.67B$1.10B26.083,000Positive NewsOPCHOption Care Health4.7811 of 5 stars$28.06-2.4%$35.75+27.4%-12.1%$4.66B$5.00B22.458,088Positive NewsBTSGBrightSpring Health Services1.3653 of 5 stars$24.08-3.2%$25.67+6.6%+85.6%$4.41B$11.27B33.6135,000Positive NewsNAKAKindlyMD2.2593 of 5 stars$9.17-9.5%N/AN/A$3.81B$2.72M0.00N/AAnalyst ForecastGap Up Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Beam Therapeutics Competitors Guardant Health Competitors Twist Bioscience Competitors 10x Genomics Competitors RadNet Competitors Sotera Health Competitors Option Care Health Competitors BrightSpring Health Services Competitors KindlyMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
